Anti-inflammatory effects of melatonin in multiple sclerosis

BioEssays

Volumn 38, Issue 10, 2016, Pages 1016-1026

  Farez, Mauricio F ^a   Calandri, Ismael L ^a   Correale, Jorge ^a   Quintana, Francisco J ^b,c  

^a Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

melatonin; MTNR1A; multiple sclerosis; ROR ; TH17 cells; Tr1 regulatory cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; LUZINDOLE; MELATONIN; MESALAZINE; NATALIZUMAB; TRANSCRIPTION FACTOR FOXP3; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CONTROLLED CLINICAL TRIAL (TOPIC); CROHN DISEASE; DISABILITY; DRUG MECHANISM; EXPERIMENTAL ALLERGIC ENCEPHALITIS; HUMAN; IMMUNOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NONHUMAN; OXIDATIVE STRESS; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; RISK FACTOR; SEASONAL VARIATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; ULCERATIVE COLITIS;

EID: 84988354824     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201600018     Document Type: Article

References (131)

1. McCord CP, Allen FP. 1917. Evidences associating pineal gland function with alterations in pigmentation. J Exp Zool 23: 207–24.
2. Lerner AB, Case JD, Takahashi Y, Lee TH, et al. 1958. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 80:2587.
3. Gonzalez-Haba MG, Garcia-Mauriño S, Calvo JR, Goberna R, et al. 1995. High-affinity binding of melatonin by human circulating T lymphocytes (CD4+). FASEB J 9: 1331–5.
4. Guerrero JM, Reiter RJ. 2002. Melatonin-immune system relationships. Curr Top Med Chem 2: 167–79.
5. Pozo D, Delgado M, Fernandez-Santos JM, Calvo JR, et al. 1997. Expression of the Mel1a-melatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen. FASEB J 11: 466–73.
6. Kokkola T, Laitinen JT. 1998. Melatonin receptor genes. Ann Med 30: 88–94.
7. Brzezinski A. 1997. Melatonin in humans. N Engl J Med 336: 186–95.
8. Tricoire H, Locatelli A, Chemineau P, Malpaux B. 2002. Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology 143: 84–90.
9. Arendt J, Wirz-Justice A, Bradtke J. 1978. Annual rhythm of serum melatonin in man. Neurosci Lett 7: 327–30.
10. Chen C-Q. 2011. Distribution, function and physiological role of melatonin in the lower gut. World J Gastroenterol 17: 3888.
11. Carrillo-Vico A, Lardone P, Álvarez-Sánchez N, Rodríguez-Rodríguez A, et al. 2013. Melatonin: buffering the immune system. Int J Mol Sci 14: 8638–83.
12. Macchi MM, Bruce JN. 2004. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 25: 177–95.
13. Ji L-D, Xu J, Wu D-D, Xie S-D, et al. 2010. Association of disease-predisposition polymorphisms of the melatonin receptors and sunshine duration in the global human populations. J Pineal Res 48: 133–41.
14. Srinivasan V, Spence WD, Trakt I, Pandi-Perumal SR, et al. 2008. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation 15: 93–101.
15. Nelson RJ, Demas GE, Klein SL, Kriegsfeld LJ. 1995. The influence of season, photoperiod, and pineal melatonin on immune function. J Pineal Res 19: 149–65.
16. Farez MF, Mascanfroni ID, Mendez-Huergo SP, Yeste A, et al. 2015. Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell 162: 1338–52.
17. Chojnacki C, Wisniewska-Jarosinska M, Walecka-Kapica E, Klupinska G, et al. 2011. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J Physiol Pharmacol 62: 327–34.
18. Forrest CM, Mackay GM, Stoy N, Stone TW, et al. 2007. Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Br J Clin Pharmacol 64: 517–26.
19. Maestroni GJ, Otsa K, Cutolo M. 2008. Melatonin treatment does not improve rheumatoid arthritis. Br J Clin Pharmacol 65: 797–8.
20. Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, et al. 2008. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 85: 335–53.
21. Nosjean O, Ferro M, Coge F, Beauverger P, et al. 2000. Identification of the melatonin-binding siteMT 3 as the quinone reductase 2. J Biol Chem 275: 31311–7.
22. Jockers R, Maurice P, Boutin JA, Delagrange P. 2008. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br J Pharmacol 154: 1182–95.
23. Wiesenberg I, Missbach M, Kahlen JP, Schräder M, et al. 1995. Transcriptional activation of the nuclear receptor RZR alpha by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acids Res 23: 327–33.
24. Jetten AM, Kurebayashi S, Ueda E. 2001. The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog Nucleic Acid Res Mol Biol 69: 205–47.
25. Slominski AT, Kim TK, Takeda Y, Janjetovic Z, et al. 2014. ROR and ROR are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D. FASEB J 28: 2775–89.
26. Lardone PJ, Guerrero JM, Fernández-Santos JM, Rubio A, et al. 2011. Melatonin synthesized by T lymphocytes as a ligand of the retinoic acid-related orphan receptor. J Pineal Res 51: 454–62.
27. Kim EJ, Yoo YG, Yang WK, Lim YS, et al. 2008. Transcriptional activation of HIF-1 by ROR and its role in hypoxia signaling. Arterioscler Thromb Vasc Biol 28: 1796–802.
28. Lardone PJ, Carrillo-Vico A, Molinero P, Rubio A, et al. 2008. A novel interplay between membrane and nuclear melatonin receptors in human lymphocytes: significance in IL-2 production. Cell Mol Life Sci 66: 516–25.
29. Reiter RJ, Calvo JR, Karbownik M, Qi W, et al. 2000. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci 917: 376–86.
30. Poeggeler B, Saarela S, Reiter RJ, Tan DX, et al. 1994. Melatonin–a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann N Y Acad Sci 738: 419–20.
31. Gray E, Thomas TL, Betmouni S, Scolding N, et al. 2008. Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol 18: 86–95.
32. Okada H, Kuhn C, Feillet H, Bach J-F. 2010. The “hygiene hypothesis” for autoimmune and allergic diseases: an update. Clin Exp Immunol 160: 1–9.
33. Kühlwein E, Irwin M. 2001. Melatonin modulation of lymphocyte proliferation and Th1/Th2 cytokine expression. J Neuroimmunol 117: 51–7.
34. Rogers N, van den Heuvel C, Dawson D. 1997. Effect of melatonin and corticosteroid on in vitro cellular immune function in humans. J Pineal Res 22: 75–80.
35. Konakchieva R, Kyurkchiev S, Kehayov I, Taushanova P, et al. 1995. Selective effect of methoxyindoles on the lymphocyte proliferation and melatonin binding to activated human lymphoid cells. J Neuroimmunol 63: 125–32.
36. Shaji AV, Kulkarni SK, Agrewala JN. 1998. Regulation of secretion of IL-4 and IgG1 isotype by melatonin-stimulated ovalbumin-specific T cells. Clin Exp Immunol 111: 181–5.
37. Cameron MJ, Arreaza GA, Zucker P, Chensue SW, et al. 1997. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J Immunol 159: 4686–92.
38. Pennline KJ, Roque-Gaffney E, Monahan M. 1994. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 71: 169–75.
39. Aoki CA, Borchers AT, Ridgway WM, Keen CL, et al. 2005. NOD mice and autoimmunity. Autoimmunity Rev 4: 373–9.
40. Conti A, Maestroni GJ. 1996. Role of the pineal gland and melatonin in the development of autoimmune diabetes in non-obese diabetic mice. J Pineal Res 20: 164–72.
41. Abraham C, Cho JH. 2009. Inflammatory bowel disease. N Engl J Med 361: 2066–78.
42. Pentney PT, Bubenik GA. 1995. Melatonin reduces the severity of dextran-induced colitis in mice. J Pineal Res 19: 31–9.
43. Nosál'ová V, Zeman M, Cerná S, Navarová J, et al. 2007. Protective effect of melatonin in acetic acid induced colitis in rats. J Pineal Res 42: 364–70.
44. Dong W-G, Mei Q, Yu J-P, Xu J-M, et al. 2003. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol 9: 1307–11.
45. Cuzzocrea S, Mazzon E, Serraino I, Lepore V, et al. 2001. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res 30: 1–12.
46. Maldonado MD, Calvo JR. 2008. Melatonin usage in ulcerative colitis: a case report. J Pineal Res 45: 339–40.
47. Calvo JR, Guerrero JM, Osuna C, Molinero P, et al. 2002. Melatonin triggers Crohn's disease symptoms. J Pineal Res 32: 277–8.
48. Choy EH, Panayi GS. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907–16.
49. Hansson I, Holmdahl R, Mattsson R. 1990. Constant darkness enhances autoimmunity to type II collagen and exaggerates development of collagen-induced arthritis in DBA/1 mice. J Neuroimmunol 27: 79–84.
50. Hansson I, Holmdahl R, Mattsson R. 1993. Pinealectomy ameliorates collagen II-induced arthritis in mice. Clin Exp Immunol 92: 432–6.
51. Hansson I, Holmdahl R, Mattsson R. 1992. The pineal hormone melatonin exaggerates development of collagen-induced arthritis in mice. J Neuroimmunol 39: 23–30.
52. Chen Q, Wei W. 2002. Effects and mechanisms of melatonin on inflammatory and immune responses of adjuvant arthritis rat. Int Immunopharmacol 2: 1443–9.
53. Tsokos GC. 2011. Systemic lupus erythematosus. N Engl J Med 365: 2110–21.
54. Jimenez-Caliani AJ, Jimenez-Jorge S, Molinero P, Fernández-Santos JM, et al. 2006. Sex-dependent effect of melatonin on systemic erythematosus lupus developed in Mrl/Mpj-Faslpr mice: it ameliorates the disease course in females, whereas it exacerbates it in males. Endocrinology 147: 1717–24.
55. Zhou L-L., Wei W, Si J-F., Yuan D-P. 2010. Regulatory effect of melatonin on cytokine disturbances in the pristane-induced lupus mice. Mediators Inflamm 2010: pii: 951210.
56. Robeva R, Tanev D, Kirilov G, Stoycheva M, et al. 2013. Decreased daily melatonin levels in women with systemic lupus erythematosus − a short report. Balkan Med J 30: 273–6.
57. Compston A, Coles A. 2008. Multiple sclerosis. The Lancet 372: 1502–17.
58. Cristiano E, Rojas J, Romano M, Frider N, et al. 2012. The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review. Mult Scler 19: 844–54.
59. Pugliatti M, Sotgiu S, Rosati G. 2002. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104: 182–91.
60. Rosati G. 2001. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 22: 117–39.
61. Dendrou CA, Fugger L, Friese MA. 2015. Immunopathology of multiple sclerosis. Nat Rev Immunol 15: 545–58.
62. Steinman L. 2014. Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol 32: 257–81.
63. Sospedra M, Martin R. 2005. Immunology of multiple sclerosis. Annu Rev Immunol 23: 683–747.
64. Miossec P, Korn T, Kuchroo VK. 2009. Interleukin-17 and type 17 helper T cells. N Engl J Med 361: 888–98.
65. Dominique LPB, Kuchroo VK. 2013. Interleukin-17 and a tale of two autoimmune diseases. Nat Med 19: 824–5.
66. Frischer JM, Weigand SD, Guo Y, Kale N, et al. 2015. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 78: 710–21.
67. Lourenco P, Shirani A, Saeedi J, Oger J, et al. 2013. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler 19: 577–84.
68. Astier AL, Meiffren G, Freeman S, Hafler DA. 2006. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest 116: 3252–7.
69. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. 2004. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199: 971–9.
70. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. 2010. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10: 490–500.
71. Sawcer S, Hellenthal G, Pirinen M, Spencer CCA, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214–9.
72. Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, et al. 2013. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 45: 1353–60.
73. Sawcer S, Franklin RJM, Ban M. 2014. Multiple sclerosis genetics. Lancet Neurol 13: 700–9.
74. Correale J, Farez M. 2007. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 61: 97–108.
75. Correale J, Fiol M, Gilmore W. 2006. The risk of relapses in multiple sclerosis during systemic infections. Neurology 67: 652–9.
76. Ascherio A, Munger KL, Lennette ET, Spiegelman D, et al. 2001. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286: 3083–8.
77. Farez MF, Fiol MP, Gaitan MI, Quintana FJ, et al. 2014. Sodium intake is associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 86: 26–31.
78. Hernan MA. 2005. Cigarette smoking and the progression of multiple sclerosis. Brain 128: 1461–5.
79. Ascherio A, Munger KL, White R, Köchert K, et al. 2014. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 71: 306.
80. Jin Y, de Pedro-Cuesta J, Söderström M, Stawiarz L, et al. 2000. Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis. J Neurol Sci 181: 56–64.
81. Spelman T, Gray O, Trojano M, Petersen T, et al. 2014. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Ann Neurol 76: 880–90.
82. Rosecrans R, Dohnal JC. 2014. Clin Biochem 47: 670–2.
83. Correale J, Ysrraelit MC, Gaitan MI. 2009. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 132: 1146–60.
84. Runia TF, Hop WCJ, de Rijke YB, Buljevac D, et al. 2012. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 79: 261–6.
85. Simpson S, Taylor B, Blizzard L, Ponsonby A-L, et al. 2010. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 68: 193–203.
86. Løken-Amsrud KI, Holmøy T, Bakke SJ, Beiske AG, et al. 2012. Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment. Neurology 79: 267–73.
87. Constantinescu CS, Hilliard B, Ventura E, Rostami A. 1997. Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology 65: 190–4.
88. Kang JC, Ahn M, Kim YS, Moon C, et al. 2001. Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J Vet Sci 2: 85–9.
89. Mathes AM, Wolf B, Rensing H. 2008. Melatonin receptor antagonist luzindole is a powerful radical scavenger in vitro. J Pineal Res 45: 337–8.
90. Álvarez-Sánchez N, Cruz-Chamorro I, López-González A, Utrilla JC, et al. 2015. Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance. Brain Behav Immun 50: 101–14.
91. Lekstrom-Himes J, Xanthopoulos KG. 1998. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem 273: 28545–8.
92. Yu X, Rollins D, Ruhn KA, Stubblefield JJ, et al. 2013. TH17 cell differentiation is regulated by the circadian clock. Science 342: 727–30.
93. Pot C, Apetoh L, Kuchroo VK. 2011. Induction of regulatory Tr1 cells and inhibition of TH17 cells by IL-27. Sem Immunol 23: 202–8.
94. Gandhi R, Kumar D, Burns EJ, Nadeau M, et al. 2010. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 11: 846–53.
95. Apetoh L, Quintana FJ, Pot C, Joller N, et al. 2010. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 11: 854–61.
96. Mascanfroni ID, Takenaka MC, Yeste A, Patel B, et al. 2015. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat Med 21: 638–46.
97. Wu HY, Quintana FJ, da Cunha AP, Dake BT, et al. 2011. In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling. PLoS ONE 6: e23618.
98. Saraiva M, O'Garra A. 2010. The regulation of IL-10 production by immune cells. Nat Rev Immunol 10: 170–81.
99. Chen S-J., Huang S-H., Chen J-W., Wang K-C., et al. 2016. Melatonin enhances interleukin-10 expression and suppresses chemotaxis to inhibit inflammation in situ and reduce the severity of experimental autoimmune encephalomyelitis. Int Immunopharmacol 31: 169–77.
100. Mascanfroni ID, Yeste A, Vieira SM, Burns EJ, et al. 2013. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol 14: 1054–63.
101. Sandyk R, Awerbuch GI. 1992. Nocturnal plasma melatonin and alpha-melanocyte stimulating hormone levels during exacerbation of multiple sclerosis. Int J Neurosci 67: 173–86.
102. Sandyk R, Awerbuch GI. 1994. Relationship of nocturnal melatonin levels to duration and course of multiple sclerosis. Int J Neurosci 75: 229–37.
103. Sandyk R, Awerbuch GI. 1994. The relationship of pineal calcification to cerebral atrophy on CT scan in multiple sclerosis. Int J Neurosci 76: 71–9.
104. Marck CH, Neate SL, Taylor KL, Weiland TJ, et al. 2016. Prevalence of comorbidities, overweight and obesity in an international sample of people with multiple sclerosis and associations with modifiable lifestyle factors. PLoS ONE 11: e0148573.
105. Melamud L, Golan D, Luboshitzky R, Lavi I, et al. 2012. Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J Neurol Sci 314: 37–40.
106. Akpınar Z, Tokgöz S, Gökbel H, Okudan N, et al. 2008. The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. Psychiatry Res 161: 253–7.
107. Wingerchuk DM, Carter JL. 2014. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 89: 225–40.
108. Bahamonde C, Conde C, Aguera E, Lillo R, et al. 2014. Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress. Eur J Pharmacol 730: 26–30.
109. Natarajan R, Einarsdottir E, Riutta A, Hagman S, et al. 2012. Melatonin pathway genes are associated with progressive subtypes and disability status in multiple sclerosis among Finnish patients. J Neuroimmunol 250: 106–10.
110. López-González A, Álvarez-Sánchez N, Lardone PJ, Cruz-Chamorro I, et al. 2015. Melatonin treatment improves primary progressive multiple sclerosis: a case report. J Pineal Res 58: 173–7.
111. Ghorbani A, Salari M, Shaygannejad V, Norouzi R. 2013. The role of melatonin in the pathogenesis of multiple sclerosis: a case-control study. Int J Prev Med 4: S180–4.
112. Schernhammer ES, Rosner B, Willett WC, Laden F, et al. 2004. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev 13: 936–43.
113. Hedström AK, Åkerstedt T, Hillert J, Olsson T, et al. 2011. Shift work at young age is associated with increased risk for multiple sclerosis. Ann Neurol 70: 733–41.
114. Hedstrom AK, Åkerstedt T, Olsson T, Alfredsson L. 2015. Shift work influences multiple sclerosis risk. Mult Scler 21: 1195–9.
115. Ebers GC. 2008. Environmental factors and multiple sclerosis. Lancet Neurol 7: 268–77.
116. Lin G-J., Huang S-H., Chen Y-W., Hueng D-Y., et al. 2009. Melatonin prolongs islet graft survival in diabetic NOD mice. J Pineal Res 47: 284–92.
117. Jimenez-Caliani AJ, Jimenez-Jorge S, Molinero P, Guerrero JM, et al. 2005. Dual effect of melatonin as proinflammatory and antioxidant in collagen-induced arthritis in rats. J Pineal Res 38: 93–9.
118. Bang J, Chang HW, Jung H-R, Cho C-H, et al. 2012. Melatonin attenuates clock gene cryptochrome1, which may aggravate mouse anti-type II collagen antibody-induced arthritis. Rheumatol Int 32: 379–85.
119. Trivedi PP, Jena GB. 2013. Melatonin reduces ulcerative colitis-associated local and systemic damage in mice: investigation on possible mechanisms. Dig Dis Sci 58: 3460–74.
120. Chung SH, Park YS, Kim OS, Kim JH, et al. 2014. Melatonin attenuates dextran sodium sulfate induced colitis with sleep deprivation: possible mechanism by microarray analysis. Dig Dis Sci 59: 1134–41.
121. Mazzon E, Esposito E, Crisafulli C, Riccardi L, et al. 2006. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res 41: 363–73.
122. Esposito E, Mazzon E, Riccardi L, Caminiti R, et al. 2008. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J Pineal Res 45: 166–73.
123. Li J-H, Yu J-P, Yu H-G, Xu X-M, et al. 2005. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm 2005: 185–93.
124. Mei Q, Xu J-M, Xiang L, Hu Y-M, et al. 2005. Change of nitric oxide in experimental colitis and its inhibition by melatonin in vivo and in vitro. Postgrad Med J 81: 667–72.
125. Necefli A, Tulumoğlu B, Giriş M, Barbaros U, et al. 2006. The effect of melatonin on TNBS-induced colitis. Dig Dis Sci 51: 1538–45.
126. Li JH, Zhou W, Liu K, Li HX, et al. 2008. Melatonin reduces the expression of chemokines in rat with trinitrobenzene sulfonic acid-induced colitis. Saudi Med J 29: 1088–94.
127. Marquez E, Sánchez-Fidalgo S, Calvo JR, la de Lastra CA, et al. 2006. Acutely administered melatonin is beneficial while chronic melatonin treatment aggravates the evolution of TNBS-induced colitis. J Pineal Res 40: 48–55.
128. Esiringü F, Tuğcu-Demiröz F, Acartürk F, Coşkun Cevher Ş, et al. 2015. Investigation of the effect of intracolonic melatonin gel formulation on acetic acid-induced colitis. Drug Deliv 25: 1–9.
129. Tahan G, Gramignoli R, Marongiu F, Aktolga S, et al. 2011. Melatonin expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic-acid-induced colitis in rats. Dig Dis Sci 56: 715–20.
130. Jimenez-Caliani AJ, Jimenez-Jorge S, Molinero P, Rubio A, et al. 2008. Treatment with testosterone or estradiol in melatonin treated females and males MRL/MpJ-Faslpr mice induces negative effects in developing systemic lupus erythematosus. J Pineal Res 45: 204–11.
131. Wu C-C, Lu K-C, Lin G-J, Hsieh H-Y, et al. 2012. Melatonin enhances endogenous heme oxygenase-1 and represses immune responses to ameliorate experimental murine membranous nephropathy. J Pineal Res 52: 460–9.